SMOF-018-CP3: A Prospective, Randomized, Controlled, Double-Blind, Parallel-Group, Phase 3 Study to Compare Safety and Efficacy of Smoflipid 20% to Intralipid 20% in Hospitalized Neonates and Infants Requiring 28 Days of Parent

Project: Research project

Project Details

StatusActive
Effective start/end date4/1/168/31/50

Funding

  • Fresenius Kabi Deutschland GmbH